Novelix Pharmaceuticals has scheduled a meeting of its Board of Directors for Saturday, August 29, 2026. The gathering will take place at the company’s registered office in Hyderabad.

The primary agenda items include considering and approving the Notice for the 32nd Annual General Meeting (AGM) and fixing its date, time, and venue. The board will also approve the Board Report along with all necessary annexures for the financial year ended March 31, 2026.

Key Agenda Items

The meeting aims to address several critical corporate governance and administrative matters:

• Approve the appointment of Mr. Gnana Prakash Gattu (DIN: 00517921) as Whole Time Director of the company.
• Appoint a Scrutinizer to oversee voting during the AGM and remote e-voting processes.
• Consider any other matter with the permission of the chair.

This intimation was issued pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was signed by Venkateshwarlu Pulluru, the current Whole-time Director.

Novelix Pharmaceuticals Ltd has entered into a land lease agreement to expand its operational footprint into microalgae cultivation. The company executed the lease deed on August 19, 2026, with Mr. Gnana Prakash Gattu, a non-executive director and member of the promoter group, to develop facilities and install glass reactor systems.

The transaction involves leasing approximately 0.925 acres (37 guntas) of land located at Survey No. 917/6A, Markook Village, near Gajwel in Siddipet District, Telangana. The lease term is set for five years, commencing from August 19, 2026. This move aligns with the company’s strategic initiative to diversify its production capabilities through specialized biological cultivation methods.

Transaction Details

The lease structure includes specific financial terms and escalation clauses designed to manage long-term occupancy costs. The arrangement is classified as a related-party transaction but was conducted on an arm’s length basis, as confirmed by the company’s disclosure under SEBI Listing Regulations.

Regulatory Disclosure

The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company cited SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, as the regulatory framework for this intimation. Venkateshwarlu Pulluru, Whole-time Director of Novelix Pharmaceuticals Ltd, signed the disclosure on August 20, 2026.

What the Numbers Show

The fixed monthly rent of ₹5,000 represents a minimal direct cash outflow for the initial phase of the project. With an escalation clause of only 5% every three years, the cost structure remains highly predictable over the five-year tenure. This low-cost entry point allows the company to test the viability of microalgae cultivation and glass reactor installations without significant upfront capital expenditure on land acquisition, shifting the risk profile towards operational execution rather than asset ownership.